About this trial

This study is a Phase 1/2, open-label study to investigate the safety and tolerability, efficacy, pharmacokinetics, and immunogenicity of Modakafusp Alfa (TAK-573) as a single agent in patients with relapsed refractory multiple myeloma

Patient Profile

The target population for this study are patients with relapsed refractory multiple myeloma

Where’s this trial being run?

Cork University Hospital, St James’s Hospital, and St Vincents University Hospital

Can I join this study / trial?

The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.

Why not Print this page and bring it with you. It will help your doctor and research team advise you.

For more detailed information


Here’s a list of questions you may have for your doctor or local cancer research team.

Summary Data

Name: TAK-573-1501
Number: 22-14
Full Title:

A Phase 1/2 Open-label Study to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Modakafusp Alfa (TAK-573) as a Single Agent in Patients With Relapsed Refractory Multiple Myeloma

Principal Investigator: Dr Kamal Fadalla
Type: Industry Sponsored


Recruitment Started: Global: TBC
Ireland: TBC
Global Recruitment Target: 236
Ireland Recruitment Target: TBC